Free Trial
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel Free VRPX Stock Alerts

Virpax Pharmaceuticals (VRPX) Competitors

Virpax Pharmaceuticals logo
$0.0001 0.00 (0.00%)
As of 05/27/2026 12:42 PM Eastern
Compare

VRPX vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Virpax Pharmaceuticals stock or one of its competitors? MarketBeat compares Virpax Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virpax Pharmaceuticals include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Virpax Pharmaceuticals compare to Ainos?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Ainos had 2 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 2 mentions for Ainos and 0 mentions for Virpax Pharmaceuticals. Ainos' average media sentiment score of 0.44 beat Virpax Pharmaceuticals' score of 0.00 indicating that Ainos is being referred to more favorably in the news media.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Ainos Neutral

Ainos has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Ainos$18.11KN/AN/AN/AN/A

Ainos' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Ainos N/A N/A N/A

Summary

Ainos beats Virpax Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Alvotech?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Alvotech has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Alvotech$586.32MN/AN/AN/AN/A

In the previous week, Alvotech had 2 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 2 mentions for Alvotech and 0 mentions for Virpax Pharmaceuticals. Alvotech's average media sentiment score of 1.44 beat Virpax Pharmaceuticals' score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Alvotech Positive

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alvotech's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Alvotech N/A N/A N/A

Summary

Alvotech beats Virpax Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Aravive?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Aravive is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
AraviveN/AN/AN/A-$0.90N/A

Aravive's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Aravive N/A N/A N/A

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.8% of Aravive shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Aravive Neutral

Summary

Aravive beats Virpax Pharmaceuticals on 5 of the 6 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

Atlantic Coastal Acquisition Corp. II's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

In the previous week, Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
Virpax Pharmaceuticals Neutral

Summary

Atlantic Coastal Acquisition Corp. II and Virpax Pharmaceuticals tied by winning 2 of the 4 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biofrontera's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

In the previous week, Biofrontera had 2 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 2 mentions for Biofrontera and 0 mentions for Virpax Pharmaceuticals. Biofrontera's average media sentiment score of 0.29 beat Virpax Pharmaceuticals' score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Neutral
Virpax Pharmaceuticals Neutral

Biofrontera has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

Summary

Biofrontera beats Virpax Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

Get Virpax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRPX vs. The Competition

Export
MetricVirpax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market CapN/A$945.20M$6.43B$12.58B
Dividend YieldN/A4.84%2.75%5.25%
P/E Ratio0.001.4621.4826.18
Price / SalesN/A138.63582.03104.40
Price / CashN/A20.0743.1356.80
Price / Book0.007.7910.527.24
Net Income-$15.19M-$3.91M$3.56B$337.24M
7 Day PerformanceN/A2.12%3.02%3.77%
1 Month PerformanceN/A70.58%4.43%5.72%
1 Year PerformanceN/A117.88%37.64%38.49%

Virpax Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRPX
Virpax Pharmaceuticals
N/A$0.00
flat		N/A-100.0%$0.00N/AN/A7
AIMDW
Ainos
N/A$0.05
-26.7%		N/A+2.4%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.22
+10.0%		N/A-86.5%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/A-85.3%$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VRPX) was last updated on 5/28/2026 by MarketBeat.com Staff.
From Our Partners
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
One page of the SpaceX S-1 will move this stock overnight
When SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...
Behind the Markets | Sponsoredtc pixel
A 25,000% opportunity
Angel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...
The Oxford Club | Sponsoredtc pixel
I paid $5,000 to hear Elon say this
One investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...
InvestorPlace | Sponsoredtc pixel
This Tech Could Be Bigger Than Apple, Amazon, and Microsoft Combined
A breakthrough technology backed by Elon Musk, Sam Altman, and Nvidia CEO Jensen Huang may hold the answer to ...
Altimetry | Sponsoredtc pixel
SMX Could Be One of the Most Interesting Small Caps Right Now
SMX (Security Matters) Public Limited is developing molecular-level markers embedded into plastics, fuels, met...
Smallcaps Daily | Sponsoredtc pixel